Ozan Pamir

CIK: 0001834681

Transaction Breakdown

Open Market Buys (P)3 (42.9%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NAGE

Niagen Bioscience, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

NAGE
Niagen Bioscience, Inc.
Jun 30, 2026
Award(A)
Direct
4.3K shares at avg. $2.71$12K
NAGE
Niagen Bioscience, Inc.
Feb 19, 2026
Award(A)
Employee Stock Options (right to buy)
Direct
62.1K shares-
NAGE
Niagen Bioscience, Inc.
Nov 14, 2025
Purchase(P)
Indirect
2.2K shares at avg. $6.85$15K
NAGE
Niagen Bioscience, Inc.
Nov 14, 2025
Purchase(P)
Direct
4.5K shares at avg. $6.81$30K
CDXC
ChromaDex Corp.
Feb 12, 2025
Award(A)
Employee Stock Options (right to buy)
Direct
17.2K shares-
CDXC
ChromaDex Corp.
Nov 22, 2024
Purchase(P)
Direct
2.9K shares at avg. $7.36$21K
CDXC
ChromaDex Corp.
Oct 21, 2024
Award(A)
Employee Stock Options (right to buy)
Direct
146.5K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	NAGE Niagen Bioscience, Inc.	Award(A)	4,255	$2.71	$11,531	Direct
Feb 19, 2026	NAGE Niagen Bioscience, Inc.	Award(A) Employee Stock Options (right to buy)	62,131	-	-	Direct
Nov 14, 2025	NAGE Niagen Bioscience, Inc.	Purchase(P)	2,220	$6.85	$15,210	Indirect
Nov 14, 2025	NAGE Niagen Bioscience, Inc.	Purchase(P)	4,465	$6.81	$30,406	Direct
Feb 12, 2025	CDXC ChromaDex Corp.	Award(A) Employee Stock Options (right to buy)	17,230	-	-	Direct
Nov 22, 2024	CDXC ChromaDex Corp.	Purchase(P)	2,907	$7.36	$21,397	Direct
Oct 21, 2024	CDXC ChromaDex Corp.	Award(A) Employee Stock Options (right to buy)	146,544	-	-	Direct

1-7 of 7 transactions

About Pamir Ozan

Pamir Ozan (SEC CIK 0001834681) files insider reports with the SEC as Chief Financial Officer of Niagen Bioscience, Inc. (NAGE).

Signal8 holds 7 ownership filings by Pamir Ozan (1 Form 3, 6 Form 4), filed between Oct 23, 2024 and Jul 8, 2026. Those filings report 7 transactions, from Oct 21, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Pamir Ozan's filings is in LOS ANGELES, CA.

Recent filings by Pamir Ozan

Jun 30, 2026: Grant or award of NAGE shares (Form 4, code A).
Feb 19, 2026: Grant or award of NAGE derivative securities (Form 4, code A).
Nov 14, 2025: Open-market purchases of NAGE shares (2 lines, Form 4, code P).
Feb 12, 2025: Grant or award of CDXC derivative securities (Form 4, code A).
Nov 22, 2024: Open-market purchase of CDXC shares (Form 4, code P).

Other insiders filing for Niagen Bioscience, Inc. (NAGE)

Lopez Carlos Luis, SVP, General Counsel
Fried Robert N, Chief Executive Officer
YU Wing Tak Wendy, Director
Ng Wang Yu Gary, Director
Cohen Ann, Director
Patrick Kristin, Director

How to read Form 4 transaction codes